Perivascular adipose tissue (PVAT) is an active endocrine and paracrine organ that modulates vascular function, with implications for the pathophysiology of cardiovascular disease (CVD). Adipocytes and stromal cells contained within PVAT produce mediators (adipokines, cytokines, reactive oxygen species and gaseous compounds) with a range of paracrine effects modulating vascular smooth muscle cell contraction, proliferation and migration. However, the modulatory effect of PVAT on the vascular system in diseases, such as obesity, hypertension and atherosclerosis, remains poorly characterized. AMP-activated protein kinase (AMPK) regulates adipocyte metabolism, adipose biology and vascular function, and hence may be a potential therapeutic target for metabolic disorders such as type 2 diabetes mellitus (T2DM) and the vascular complications associated with obesity and T2DM. The role of AMPK in PVAT or the actions of PVAT have yet to be established, however. Activation of AMPK by pharmacological agents, such as metformin and thiazolidinediones, may modulate the activity of PVAT surrounding blood vessels and thereby contribute to their beneficial effect in cardiometabolic diseases. This review will provide a current perspective on how PVAT may influence vascular function via AMPK. We will also attempt to demonstrate how modulating AMPK activity using pharmacological agents could be exploited therapeutically to treat cardiometabolic diseases.
AbbreviationsACC, acetyl-CoA carboxylase; AICAR, 5-aminoimidazole-4-carboxamide 1-β-D-ribonucleoside; AMPK, AMP-activated PK; BAT, brown adipose tissue; CAD, coronary artery disease; CTRP12, C1q/TNF-related protein-12; CVD, cardiovascular disease; DIO, diet-induced obesity; ER, endoplasmic reticulum; GLUT4, glucose transporter type 4; HDL, high-density lipoprotein; HFD, high-fat diet; HGF, hepatocyte growth factor; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; LKB1, liver kinase B1; MPO, myeloperoxidase; mTOR, mammalian target of rapamycin; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; PVAT, perivascular adipose tissue; PVRFs, PVAT-derived relaxant factors; SMCs, smooth muscle cells; SOD, superoxide dismutase; T2DM, type 2 diabetes mellitus; TZDs, thiazolidinediones; WAT, white adipose tissue
IntroductionCardiovascular disease (CVD) remains the most common cause of death worldwide. The inexorable rise in diabetes and obesity will continue to shorten many lives and be a huge burden on healthcare budgets throughout the world (Trujillo and Scherer, 2006). Evidence from several studies, including the Framingham Heart Study, has demonstrated that obesity is closely associated with increased vulnerability to insulin resistance, type 2 diabetes mellitus (T2DM), hypertension, coronary artery disease (CAD), myocardial infarction (MI) and sudden death, congestive heart failure and stroke (Henry et al., 2002; Galassi et al., 2006). However, the pathophysiological mechanisms underlying the relationship between obesity and CVD remain poorly understood. Dysfunctional pe...